EP1417203A4 - S-6-hydroxy-buspirone - Google Patents

S-6-hydroxy-buspirone

Info

Publication number
EP1417203A4
EP1417203A4 EP02747078A EP02747078A EP1417203A4 EP 1417203 A4 EP1417203 A4 EP 1417203A4 EP 02747078 A EP02747078 A EP 02747078A EP 02747078 A EP02747078 A EP 02747078A EP 1417203 A4 EP1417203 A4 EP 1417203A4
Authority
EP
European Patent Office
Prior art keywords
buspirone
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02747078A
Other languages
German (de)
French (fr)
Other versions
EP1417203A1 (en
Inventor
Joseph P Yevich
Robert F Mayol
Jianqing Li
Frank Yocca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP1417203A1 publication Critical patent/EP1417203A1/en
Publication of EP1417203A4 publication Critical patent/EP1417203A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02747078A 2001-07-24 2002-07-22 S-6-hydroxy-buspirone Withdrawn EP1417203A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30742801P 2001-07-24 2001-07-24
US307428P 2001-07-24
PCT/US2002/023341 WO2003010161A1 (en) 2001-07-24 2002-07-22 S-6-hydroxy-buspirone

Publications (2)

Publication Number Publication Date
EP1417203A1 EP1417203A1 (en) 2004-05-12
EP1417203A4 true EP1417203A4 (en) 2005-08-10

Family

ID=23189723

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02747078A Withdrawn EP1417203A4 (en) 2001-07-24 2002-07-22 S-6-hydroxy-buspirone

Country Status (3)

Country Link
US (1) US6821976B2 (en)
EP (1) EP1417203A4 (en)
WO (1) WO2003010161A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069251A1 (en) * 1999-08-05 2003-04-10 Yevich Joseph P. Antianxiety composition
CN1674904A (en) * 2002-08-12 2005-09-28 布里斯托尔-迈尔斯斯奎布公司 Process for hydroxyazapirones
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド 5HT receptor-mediated neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
WO2008086483A2 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
EP2167065A1 (en) * 2007-06-18 2010-03-31 The General Hospital Corporation Combination therapy for depression
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
PL3160464T3 (en) * 2014-06-26 2018-12-31 Contera Pharma Aps 6-hydroxybuspirone for use in the treatment of movement disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US6150365A (en) * 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
WO2003009851A1 (en) * 2001-07-24 2003-02-06 Bristol-Myers Squibb Company R-6-hydroxy-buspirone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593331B2 (en) * 2001-04-17 2003-07-15 Laboratories Upsa Method for treatment of pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US6150365A (en) * 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
WO2003009851A1 (en) * 2001-07-24 2003-02-06 Bristol-Myers Squibb Company R-6-hydroxy-buspirone

Also Published As

Publication number Publication date
US6821976B2 (en) 2004-11-23
EP1417203A1 (en) 2004-05-12
US20030022899A1 (en) 2003-01-30
WO2003010161A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
DE60217162D1 (en) Tetrafluorethen-perfluorbutylethen-copolymer
DE60209787D1 (en) Flächiges implantat
DE50202400D1 (en) Baw-resonator
DE50201180D1 (en) Organopolysiloxan/polyharnstoff/polyurethan-blockcopolymere
DE60213216D1 (en) Metalloproteinaseinhibitoren
DE60217478D1 (en) Sychrongleichrichter
DE50211022D1 (en) Heteroarylcarbonsäureamide
DE60214551D1 (en) Modulares airbagaufblassystem
DE60141364D1 (en) Polyphenylensulfidharzzusammensetzung
DE60210819D1 (en) Pyrazolopyridazinderivate
DE60141362D1 (en) Ösophagus-stoma-knopf
DE50202633D1 (en) Ophthalmoskop
EP1417203A4 (en) S-6-hydroxy-buspirone
AU2002360430A8 (en) 14-methyl-epothilones
DE60107296D1 (en) Kabelverstärkerverbindungsanordnung
DE60204140D1 (en) 5-ethyl-imidazotriazinone
DE60216319D1 (en) Heteroaryl-substituierte aminocyclohexan-derivate
DE50203686D1 (en) Substituierte c-furan-2-yl-methylamin- und c-thiophen-2-yl-methylamin-derivate
DE50206483D1 (en) Displaymodul
DE50201028D1 (en) Diarylgelbpigmentpraeparationen
DE50214962D1 (en) Heterocyclylarylsulfonamide
DE60206072D1 (en) Aroylpyridinone
AU2002313943A8 (en) Electromobile
AU2001100134A4 (en) Enviro-trap
CA93647S (en) Fauteuil

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YOCCA, FRANK

Inventor name: LI, JIANQING

Inventor name: MAYOL, ROBERT, F.

Inventor name: YEVICH, JOSEPH, P.

A4 Supplementary search report drawn up and despatched

Effective date: 20050629

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050917